Eikon reports Q3 2026 results, ESMO oncology data and new prostate cancer INDNov 12Quarterly updateAkari Therapeutics PlcAtrium Therapeutics
Bicara reaches substantial enrollment in HPV-negative head and neck cancer trialNov 9Quarterly updateArriVent BioPharma, Inc.Bicara Therapeutics
Novartis terminates phase III KontRASt-02 trial of JDQ443 in lung cancerNov 6Trial updateNovartisopnurasib
AstraZeneca completes AZD4144-itraconazole PK study; posts five trial records this weekNov 6Weekly roundup, 12 itemsanifrolumab-fniaAstraZenecaUpdated
Arvinas reports Q3 2026 results, dosing starts in new HPK1 trialNov 3Quarterly updateARV-6723Arvinas Inc.
Pfizer raises 2026 guidance after Q3, reports pipeline progress and new CFONov 3Quarterly updateBioNTech SEC4 Therapeutics, Inc.
Merck registers new MK-8644 psoriasis trial; RA and HIV/HPV vaccine trials continueOct 30Weekly roundup, 11 itemscabazitaxeldexamethasoneUpdated
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
BioNTech, BMS report Phase 2 pumitamig data in NSCLC after immunotherapy progressionOct 26Clinical readoutBioNTech SEBristol Myers SquibbUpdated
Imunon agrees to sell ThermoDox rights to VoxelDox TherapeuticsOct 21Clinical readoutEikon TherapeuticsGenmab A/S
Fred Hutchinson posts Phase II acalabrutinib results; AstraZeneca's AZD0780 LDL-C trial completesOct 16Weekly roundup, 11 itemsacalabrutinibAstraZenecaUpdated
Arcus Biosciences completes Phase 1/1b trial of AB801 in advanced malignanciesOct 9Trial updateAB801Arcus Biosciences, Inc.
Karyopharm posts results for selinexor trial testing hepatic impairment dosing, combinationsOct 9Trial updateKaryopharm Therapeutics Incselinexor
Vir Biotechnology says FDA grants Fast Track to VIR-5500 for prostate cancerOct 8Regulatory milestoneAstellas PharmaVir Biotechnology, Inc.
BeyondSpring completes sale of BeyondSpring Ltd. to Biolin InvestmentOct 6M&ABeyondSpring Pharmaceuticals Inc.
Mirati's SAPPHIRE trial in NSCLC terminated, results posted on ClinicalTrials.govSep 30Trial updateBristol Myers Squibbnivolumab
BeyondSpring files $11.9 million at-the-market offering with CitizensSep 29FinancingBeyondSpring Pharmaceuticals Inc.
AbbVie registers Phase 3 trial of telisotuzumab adizutecan in NSCLCSep 16Trial updateAbbVietelisotuzumab adizutecan
Pyxis Oncology reports updated Phase 1 data for MICVO in head and neck cancerSep 9Clinical readoutPyxis Oncology, Inc
BeiGene posts results for zanidatamab combo trial in HER2-positive breast, gastric cancersSep 2Trial updateBeiGenetislelizumab
BeyondSpring updates Plinabulin data, names new CEO, reports Q2 2026 resultsAug 14Quarterly updateBeyondSpring Pharmaceuticals Inc.
Candel targets Q4 2026 BLA for prostate cancer therapy, opens NSCLC phase 3 trialAug 13Quarterly updateCandel Therapeutics, Inc.
Vir reports Week 96 SOLSTICE data, ECLIPSE program fully enrolled, VIR-5500 expansion underwayAug 5Quarterly updateVir Biotechnology, Inc.VIR-5500
ORIC Pharmaceuticals starts Phase 3 Himalayas-1 trial, adds Bayer supply dealAug 3Quarterly updateORIC Pharmaceuticals
NuCana's NuTide:303 trial for NUC-3373 combos terminated; results posted with 19 enrolledJul 23Trial updatefosifloxuridine nafalbenamideNuCana plc
ORIC Pharmaceuticals registers Phase 3 Himalayas-1 trial for rinzimetostat in mCRPCJul 23Trial updateBayerdarolutamide
AstraZeneca posts PASSAGE Phase 4 tezepelumab results; registers new prostate, lung, and NF2 trialsJul 17Weekly roundup, 6 itemsAstraZenecaosimertinib
Telix and FDA align on ProstACT Global Phase 3 protocol, IND amendment pendingJul 2Clinical readoutTelix Pharmaceuticals Ltd
GSK's DREAMM 12 posts results with 36 enrolled; COSTAR Lung stays active, not recruitingJul 1Weekly roundup, 2 itemsbelantamabbelantamab mafodotin